Pancreatic and multiorgan resection with inferior vena cava reconstruction for retroperitoneal leiomyosarcoma
© Stauffer et al; licensee BioMed Central Ltd. 2009
Received: 11 September 2008
Accepted: 06 January 2009
Published: 06 January 2009
Inferior vena cava (IVC) leiomyosarcoma is a rare tumor of smooth muscle origin. It is often large by the time of diagnosis and may involve adjacent organs. A margin-free resection may be curative, but the resection must involve the tumor en bloc with the affected segment of vena cava and locally involved organs. IVC resection often requires vascular reconstruction, which can be done with prosthetic graft.
We describe a 39-year-old man with an IVC leiomyosarcoma that involved the adrenal gland, distal pancreas, and blood supply to the spleen and left kidney. Tumor excision involved en bloc resection of all involved organs with reimplantation of the right renal vein and reconstruction of the IVC with a polytetrafluoroethylene graft. The patient recovered without renal insufficiency, graft infection, or other complications. Follow-up abdominal imaging at 1 year showed a patent IVC graft and no locally recurrent tumor. Prosthetic graft provides a sufficient diameter and length for replacement conduit in extensive resection of IVC leiomyosarcoma.
To our knowledge, this is the first case of resection of an IVC sarcoma with prosthetic graft reconstruction in combination with pancreatic resection. Aggressive surgical resection including vascular reconstruction is warranted for select IVC tumors to achieve a potentially curative outcome.
Inferior vena cava (IVC) leiomyosarcomas are rare malignancies; fewer than 300 have been reported in literature. This mesenchymal tumor is derived from medial smooth muscle cells and most often originates from the IVC segment between the hepatic veins and the renal veins . It is most commonly diagnosed in women in their sixth decade, and the tumors often reach large dimensions before detection because of an absence of symptoms [2–6]. They are slow-growing and potentially curable by complete and margin-free resection but are well known to present difficulties in resection because of their location and involvement of surrounding organs and vascular structures.
Locally involved organs are commonly the kidney, adrenal gland, and liver [2, 3, 5–8]. Radical resection of the tumor en bloc with the affected segment of the vena cava has been shown in multiple studies to be a feasible option with improved survival [1–3, 5, 6, 9, 10]. The pancreas is not often involved with this retroperitoneal sarcoma, and pancreas resection may increase the risk of graft infection. Indeed, to our knowledge, a concomitant retroperitoneal sarcoma resection and pancreas resection with IVC interposition grafting have not been reported in literature. We describe a patient with a leiomyosarcoma involving the left kidney, left adrenal gland, and distal pancreas, which required IVC resection followed by reconstruction with polytetrafluoroethylene (PTFE).
Primary leiomyosarcoma of the IVC is a rare malignant tumor first described in 1891 by Perl at autopsy. The most common presenting symptoms are abdominal pain, palpable abdominal mass, and lower limb edema . However, even with extensive caval involvement, severe venous obstructive symptoms are not often seen, probably because of the development of extensive venous collaterals, which maintain adequate flow around the level of obstruction . The segment of IVC between the renal veins and the hepatic veins (level II or middle segment) is the most commonly affected location for all primary vascular tumors [3, 5, 6].
IVC leiomyosarcomas are relatively resistant to chemotherapy and radiotherapy, and complete resection of the tumor is the only known method for a chance of cure. The prognosis for leiomyosarcoma of the IVC treated medically is poor, with an average survival of less than 3 months . However, in the past 2 decades, aggressive surgical resection has yielded notable survival benefits, even for patients with metastatic disease. While data are confined to a relatively small number of patients, 5-year survival rates have been shown to be as high as 31% to 53% [3, 5–8, 10] after complete resection of level II IVC leiomyosarcoma.
Early diagnosis is rare, and the tumors often invade surrounding organs. The amount of vascular involvement by the retroperitoneal tumor accounts for the high surgical risk and technical difficulties seen during attempts at complete resection. Accurate preoperative imaging to determine the extent of the tumor is essential for adequate planning, and magnetic resonance imaging is the preferred modality.
Caval management after IVC resection is controversial. Options include primary repair, autologous patching, ligation, or reconstruction with prosthetic graft. Extensive venous involvement and large tumor size often preclude short segment resection with simple repair or patching. Ligation of the IVC is favored by some and has been shown to be well tolerated and generally safe, especially in those with preoperative IVC thrombosis [1, 3]. However, there is a risk of late complications such as pain, swelling, and skin breakdown from severe lower extremity edema. Long-term anticoagulation may be necessary in these patients. Suprarenal IVC tumor involvement treated with IVC ligation can place a patient at serious risk for renal insufficiency. Restoration of flow to the right renal vein by reimplantation (or pelvic kidney autotransplantation) is mandatory to maintain right kidney function, but optional for the left renal vein because of the left kidney's considerable collateral drainage through the adrenal, inferior phrenic, gonadal, and paravertebral vessels .
Because of the considerable size of these tumors at diagnosis, wide retroperitoneal dissection is often necessary for complete tumor resection, disrupting the preexisting venous channels. This dissection negates any collateral flow that achieved venous decompression preoperatively. Long segments of tumor involvement of the IVC necessitate ligation of a larger amount of lumbar veins that serve as collaterals. Kieffer et al  used a proximal pressure reading of 30 mm Hg or more in the IVC as an indication for caval reconstruction and found reconstruction to be necessary in most cases. PTFE is the most commonly used prosthetic material and has been shown to be a suitable replacement for the IVC with excellent long-term patency [5, 6, 8–10, 12]. Infection and graft thrombosis are the 2 major complications of this type of reconstruction, but both are rare. Graft thrombosis may or may not have any clinical importance, and methods used to decrease its incidence include the use of ring-reinforced PTFE to prevent compression, short-term anticoagulation, and placement of an arteriovenous fistula to augment flow .
Although increasing the complexity of the operation, partial or total resection of locally involved organs is necessary for complete tumor removal because prognosis is highly dependent on a tumor-free margin. Patients with inadequate resections are at high risk for local recurrence, causing death from a retroperitoneal sarcoma . Multivisceral resection, especially of enteric organs, may make a surgeon hesitant to place autogenous material for reconstruction. However, PTFE graft infection after IVC replacement has been shown to be a rare occurrence in several large series [5, 6, 8–10, 12]. Measures to decrease risk of graft contamination include routine perioperative intravenous antibiotics, antibiotic irrigation of the abdomen, and coverage of the graft with omentum for graft isolation. However, to our knowledge, resection of the pancreas has not been reported in combination with IVC resection and reconstruction. Pancreatic fistula occurs in up to 23% to 26% of cases of distal pancreatectomy for malignancy [13, 14]. Pancreatic leak would have serious consequences in the face of prosthetic vascular material in close proximity and could result in catastrophic graft infection. Measures to prevent pancreatic contamination of the graft should be undertaken, including ensuring adequate distal pancreatic stump closure and providing sufficient closed suction drainage of the pancreatic bed.
Although often not curative, aggressive surgical resection combined with chemoradiotherapy has been definitively shown to prolong survival in patients with IVC leiomyosarcomas. Vascular reconstruction is often required, and prosthetic replacement of the IVC with PTFE has been shown to be a safe option for retroperitoneal sarcomas. Graft-related complications are low but may be increased by tumor involvement of the pancreas. However, pancreatic involvement did not preclude resection in this case, giving the patient the survival benefit of a margin-free radical en bloc resection.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
inferior vena cava
- Mingoli A, Feldhaus RJ, Cavallaro A, Stipa S: Leiomyosarcoma of the inferior vena cava: analysis and search of world literature on 141 patients and report of three new cases. J Vasc Surg. 1991, 14: 688-699. 10.1067/mva.1991.30426.View ArticlePubMedGoogle Scholar
- Dzsinich C, Gloviczki P, van Heerden JA, Nagorney DM, Pairolero PC, Johnson CM, Hallett JW, Bower TC, Cherry KJ: Primary venous leiomyosarcoma: a rare but lethal disease. J Vasc Surg. 1992, 15: 595-603. 10.1067/mva.1992.34346.View ArticlePubMedGoogle Scholar
- Hollenbeck ST, Grobmyer SR, Kent KC, Brennan MF: Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg. 2003, 197: 575-579. 10.1016/S1072-7515(03)00433-2.View ArticlePubMedGoogle Scholar
- Burke AP, Virmani R: Sarcomas of the great vessels: a clinicopathologic study. Cancer. 1993, 71: 1761-1773. 10.1002/1097-0142(19930301)71:5<1761::AID-CNCR2820710510>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Kieffer E, Alaoui M, Piette JC, Cacoub P, Chiche L: Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg. 2006, 244: 289-295. 10.1097/01.sla.0000229964.71743.db.PubMed CentralView ArticlePubMedGoogle Scholar
- Hines OJ, Nelson S, Quinones-Baldrich WJ, Eilber FR: Leiomyosarcoma of the inferior vena cava: prognosis and comparison with leiomyosarcoma of other anatomic sites. Cancer. 1999, 85: 1077-1083. 10.1002/(SICI)1097-0142(19990301)85:5<1077::AID-CNCR10>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
- Mingoli A, Sapienza P, Cavallaro A, Di Marzo L, Burchi C, Giannarelli D, Feldhaus RJ: The effect of extent of caval resection in the treatment of inferior vena cava leiomyosarcoma. Anticancer Res. 1997, 17: 3877-3881.PubMedGoogle Scholar
- Dew J, Hansen K, Hammon J, McCoy T, Levine EA, Shen P: Leiomyosarcoma of the inferior vena cava: surgical management and clinical results. Am Surg. 2005, 71: 497-501.PubMedGoogle Scholar
- Schwarzbach MH, Hormann Y, Hinz U, Leowardi C, Bockler D, Mechtersheimer G, Friess H, Buchler MW, Allenberg JR: Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement. J Vasc Surg. 2006, 44: 46-55. 10.1016/j.jvs.2006.03.001.View ArticlePubMedGoogle Scholar
- Illuminati G, Calio' FG, D'Urso A, Giacobbi D, Papaspyropoulos V, Ceccanei G: Prosthetic replacement of the infrahepatic inferior vena cava for leiomyosarcoma. Arch Surg. 2006, 141: 919-924. 10.1001/archsurg.141.9.919.View ArticlePubMedGoogle Scholar
- Kraybill WG, Callery MP, Heiken JP, Flye MW: Radical resection of tumors of the inferior vena cava with vascular reconstruction and kidney autotransplantation. Surgery. 1997, 121: 31-36. 10.1016/S0039-6060(97)90179-3.View ArticlePubMedGoogle Scholar
- Bower TC, Nagorney DM, Cherry KJ, Toomey BJ, Hallett JW, Panneton JM, Gloviczki P: Replacement of the inferior vena cava for malignancy: an update. J Vasc Surg. 2000, 31: 270-281. 10.1016/S0741-5214(00)90158-7.View ArticlePubMedGoogle Scholar
- Pannegeon V, Pessaux P, Sauvanet A, Vullierme MP, Kianmanesh R, Belghiti J: Pancreatic fistula after distal pancreatectomy: predictive risk factors and value of conservative treatment. Arch Surg. 2006, 141: 1071-1076. 10.1001/archsurg.141.11.1071.View ArticlePubMedGoogle Scholar
- Fahy BN, Frey CF, Ho HS, Beckett L, Bold RJ: Morbidity, mortality, and technical factors of distal pancreatectomy. Am J Surg. 2002, 183: 237-241. 10.1016/S0002-9610(02)00790-0.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.